168 related articles for article (PubMed ID: 37488154)
1. Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.
Schettini F; De Bonis MV; Strina C; Milani M; Ziglioli N; Aguggini S; Ciliberto I; Azzini C; Barbieri G; Cervoni V; Cappelletti MR; Ferrero G; Ungari M; Locci M; Paris I; Scambia G; Ruocco G; Generali D
Sci Rep; 2023 Jul; 13(1):11951. PubMed ID: 37488154
[TBL] [Abstract][Full Text] [Related]
2. Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
Schettini F; Corona SP; Giudici F; Strina C; Sirico M; Bernocchi O; Milani M; Ziglioli N; Aguggini S; Azzini C; Barbieri G; Cervoni V; Cappelletti MR; Molteni A; Lazzari MC; Ferrero G; Ungari M; Marasco E; Bruson A; Xumerle L; Zago E; Cerra D; Loddo M; Williams GH; Paris I; Scambia G; Generali D
Front Oncol; 2021; 11():686776. PubMed ID: 34262869
[TBL] [Abstract][Full Text] [Related]
3.
Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
Anticancer Res; 2023 Jan; 43(1):127-136. PubMed ID: 36585209
[TBL] [Abstract][Full Text] [Related]
4. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.
Koo HR; Park JS; Kang KW; Han W; Park IA; Moon WK
Eur Radiol; 2015 Nov; 25(11):3314-21. PubMed ID: 25903708
[TBL] [Abstract][Full Text] [Related]
5. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
Yue Y; Cui X; Bose S; Audeh W; Zhang X; Fraass B
Breast Cancer Res Treat; 2015 Oct; 153(3):607-16. PubMed ID: 26346756
[TBL] [Abstract][Full Text] [Related]
6. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Biard L; Lehmann-Che J; Teixeira L; Bouhidel FA; Poirot B; Bertheau P; Merlet P; Espié M; Resche-Rigon M; Sotiriou C; de Cremoux P
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1279-1288. PubMed ID: 29616304
[TBL] [Abstract][Full Text] [Related]
7. Additional value of
van Ramshorst MS; Teixeira SC; Koolen BB; Pengel KE; Gilhuijs KG; Wesseling J; Rodenhuis S; Valdés Olmos RA; Rutgers EJ; Vogel WV; Sonke GS; Vrancken Peeters MT
Cancer Imaging; 2017 May; 17(1):15. PubMed ID: 28545563
[TBL] [Abstract][Full Text] [Related]
8. Role of
Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
[TBL] [Abstract][Full Text] [Related]
9. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
10. Association of
Önner H; Coskun N; Erol M; Eren Karanis Mİ
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(1):11-16. PubMed ID: 34991831
[TBL] [Abstract][Full Text] [Related]
11. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
12. The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer.
Sasada S; Shiroma N; Goda N; Kajitani K; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
Breast Cancer Res Treat; 2019 Oct; 177(3):651-657. PubMed ID: 31267329
[TBL] [Abstract][Full Text] [Related]
13. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
14. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
[TBL] [Abstract][Full Text] [Related]
15. Relationship between FDG-PET and the immune microenvironment in breast cancer.
Kitajima K; Higuchi T; Fujimoto Y; Ishikawa E; Yokoyama H; Komoto H; Inao Y; Yamakado K; Miyoshi Y
Eur J Radiol; 2023 Jan; 158():110661. PubMed ID: 36542934
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Correlation of
Mayoral M; Paredes P; Saco A; Fusté P; Perlaza P; Tapias A; Fernandez-Martinez A; Vidal L; Ordi J; Pavia J; Martinez-Roman S; Lomeña F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):80-86. PubMed ID: 28869177
[TBL] [Abstract][Full Text] [Related]
18. Correlation between
Murakami W; Tozaki M; Sasaki M; Hida AI; Ohi Y; Kubota K; Sagara Y
Eur J Radiol; 2020 Feb; 123():108773. PubMed ID: 31918248
[TBL] [Abstract][Full Text] [Related]
19. Correlation of 18-fluorodeoxyglucose uptake values on PET-CT scan with histological prognostic markers in breast cancer.
Muduly DK; Ephraim R; Sultania M; Ray S; Bhoriwal S; Pathak M; Kar M
Asia Pac J Clin Oncol; 2023 Apr; 19(2):e106-e110. PubMed ID: 35799361
[TBL] [Abstract][Full Text] [Related]
20. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
